External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath… (NCT07496086) | Clinical Trial Compass
RecruitingNot Applicable
External Oblique Intercostal Block Versus Transversus Abdominis Plane Combined With Rectus Sheath Block on Postoperative Pain in Laparoscopic Radical Gastrectomy
China100 participantsStarted 2026-03-20
Plain-language summary
Postoperative pain is highly prevalent following laparoscopic radical gastrectomy. Although Transversus abdominis plane block combined with rectus sheath block(TAP+RSB） can effectively alleviate this pain, it still has many limitations. The external oblique intercostal plane block (EOIB) is a novel nerve block technique that may provide well postoperative analgesia for upper abdominal surgery. Therefore, this study employs a non-inferiority randomized controlled trial design to verify that the analgesic effect of EOIB is not inferior to that of ESPB, thereby offering more options for regional analgesia strategies in laparoscopic radical gastrectomy.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged over 18 years
* Classified as ASA I-III
* Scheduled for elective laparoscopic radical gastrectomy under general anesthesia
* Voluntarily participated and provided written informed consent.
Exclusion Criteria:
* Chronic opioid dependence or prior use of analgesic medications for \>3 months;
* Inability to communicate due to severe dementia, language barriers, or terminal illness;
* History of central and/or peripheral nervous system disorders;
* Severe renal insufficiency (serum creatinine \>442 μmol/L or requiring renal replacement therapy) or severe hepatic insufficiency (Child-Pugh class C);
* Allergy to local anesthetics.
* Expected to be transferred to ICU after surgery.
* Refuse patient control agenesia after surgery.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Cumulative opioid consumption within 24 hours postoperatively
Timeframe: 24 hours after surgery
Trial details
NCT IDNCT07496086
SponsorGeneral Hospital of Ningxia Medical University